Financial Performance - In 2024, the company achieved total revenue of RMB 80.80 million, a decrease of 39.96% compared to the previous year[4] - The net profit attributable to the parent company was RMB -93.50 million, down 31.70% year-on-year[6] - The company reported a total asset value of RMB 153.24 million at the end of 2024, a decrease of 6.08% from the beginning of the period[6] - The significant changes in financial metrics were primarily due to declining product sales, price reductions, and impairment provisions[10] Asset Management - The company plans to recognize an asset impairment provision of approximately RMB 23.71 million for products expected to be unsold due to nearing expiration[7] Pricing Strategy - The company adjusted the price of its quadrivalent influenza vaccine, reducing the price from RMB 128 to RMB 88 per dose, impacting revenue[7] Market Strategy - The company aims to enhance public awareness of vaccination to increase domestic influenza vaccine uptake in 2025[9] - The company will accelerate the production and sales of influenza vaccines to ensure timely market availability for the 2025-2026 season[9] Quality Assurance - The company intends to maintain high standards of product quality and strict compliance with GMP requirements[9] Risk Management - The company emphasizes the importance of risk awareness and the preliminary nature of the financial data provided[11]
金迪克(688670) - 2024 Q4 - 年度业绩